Table 1.
Study Treatment | Mean BaselineLDL-C (mg/dL)a | Mean BaselineHDL-C (mg/dL)a | Mean Baseline TG (mg/dL)a | Treatment Period Duration | Mean Common CIMT Change from Baseline, mm (SD) |
---|---|---|---|---|---|
Taylor et al. (2004) [37] | |||||
Niacin | 87 | 39 | 154 | 12 months | 0.014 (0.104) |
Placebo | 91 | 40 | 172 | 0.044 (0.100) | |
Difference | −0.03 | ||||
Sidhu et al. (2004) [44] | |||||
Rosiglitazone | 98 | 45 | 114 | 48 weeks | −0.012 (0.094) |
Placebo | 102 | 47 | 137 | 0.031 (0.096) | |
Difference | −0.043 | ||||
Hanefeld et al. (2004) [46] | |||||
Acarbose | Not | 51 | 212 | ≥36 months | 0.007 (0.019)b |
Placebo | reported | 49 | 235 | 0.013 (0.018)b | |
Difference | −0.006b | ||||
Mazzone et al. (2006) [36] | |||||
Pioglitazone | 113.8 | 47.1 | 178.6 | 72 weeks | −0.001 |
Glimepiride | 111.3 | 47.6 | 170.4 | 0.012 | |
Difference | −0.013 | ||||
Hodis et al. (2006) [42] | |||||
Troglitazone | 170 | 50 | 115 | 24 months | 0.0030 (0.021)b |
Placebo | 182 | 50 | 115 | 0.0066 (0.021)b | |
Difference | −0.0036b | ||||
Hedblad et al. (2007) [41] | |||||
Rosiglitazone | 135 | 50 | 150 | 12 months | 0.01 (0.073) |
Placebo | 131 | 50 | 150 | 0.017 (0.076) | |
Difference | −0.007 | ||||
Crouse et al. (2007) [34] | |||||
Rosuvastatin | 155 | 50 | 126 | 24 months | 0.0004 (0.019)b |
Placebo | 154 | 49 | 134 | 0.0088 (0.02)b | |
Difference | −0.0085b | ||||
Kastelein et al. (2007) [38] | |||||
Atorvastatin | 139 | 52 | 97c | 24 months | −0.0014 (0.027)b |
Atorvastatin + torcetrapib | 138 | 53 | 97c | 0.0038 (0.027)b | |
Difference | −0.0052b | ||||
Kastelein et al. (2008) [43] | |||||
Simvastatin | 318 | 47 | 160c | 24 months | 0.0024 (0.077) |
Simvastatin + ezetimibe | 319 | 47 | 157c | 0.0019 (0.079) | |
Difference | 0.0005 | ||||
Hiukka et al. (2008) [31] | |||||
Fenofibrate | 120 | 45 | 136 | 60 months | 0.0050 (0.060)b |
Placebo | 118 | 43 | 147 | 0.0069 (0.054)b | |
Difference | −0.0019b | ||||
Meuwese et al. (2009) [35] | |||||
Pactimibe | 141 | 51 | 135 | 12 months | 0.019 (0.099)d |
Placebo | 139 | 52 | 136 | 0.005 (0.085)d | |
Difference | 0.014 | ||||
Taylor et al. (2009) [45] | |||||
Ezetimibe | 84 | 43 | 122c | 14 months | −0.0007 (0.037) |
Niacin | 81 | 43 | 126c | −0.0142 (0.040) | |
Difference | 0.0135 | ||||
Davidson et al. (2009) [40] | |||||
Pomegranate juice | 139 | 55 | 153 | 18 months | 0.005 (0.048)b |
Control | 142 | 56 | 144 | 0.005 (0.048)b | |
Difference | 0.00b |
C cholesterol; CIMT carotid intima-media thickness; HDL high-density lipoprotein; LDL low-density lipoprotein; TG triglyceride
aReported values in mmol/L were converted to mg/dL by dividing cholesterol values by 0.02586 and TG values by 0.01130
bChange per year
cMedian values
dIncluded common, bulb, and internal segments